Soleno Therapeutics Securities Class Action
Soleno Therapeutics · Common stock and DCCR Phase 3 clinical trial program · Other
About this case
A securities class action was filed in the U.S. District Court for the Northern District of California on behalf of investors who purchased or acquired Soleno Therapeutics common stock between March 26, 2025, and August 4, 2025. The lawsuit alleges that Soleno Therapeutics and certain senior officers made misrepresentations concerning the company’s Phase 3 clinical trial program for DCCR; the current procedural stage is not specified.
Case overview
- Defendant company
- Soleno Therapeutics
- Product or service
- Common stock and DCCR Phase 3 clinical trial program
- Case status
- Other
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Lead Plaintiff Application
Participation information
Availability is based on each listed participation option and its deadline.
Lead Plaintiff Application
Investors who purchased or acquired Soleno Therapeutics common stock between March 26, 2025, and August 4, 2025, inclusive, could seek appointment as lead plaintiff.
File the required papers by May 5, 2026.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.